Filtered By:
Specialty: Cardiology
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 1444 results found since Jan 2013.
Plasma ANGPTL8 Levels and Risk for Secondary Cardiovascular Events in Japanese Patients With Stable Coronary Artery Disease Receiving Statin Therapy
CONCLUSIONS: Monitoring ANGPTL8 levels over time might be useful to assess residual risk of cardiovascular secondary events in patients with cardiovascular disease undergoing statin therapy.PMID:37259862 | DOI:10.1161/ATVBAHA.122.318880
Source: Arteriosclerosis, Thrombosis and Vascular Biology - June 1, 2023 Category: Cardiology Authors: Jun Morinaga Kosuke Kashiwabara Daisuke Torigoe Yusuke Okadome Kenichi Aizawa Kohei Uemura Ai Kurashima Eiji Matsunaga Hirotaka Fukami Haruki Horiguchi Michio Sato Taichi Sugizaki Keishi Miyata Tsuyoshi Kadomatsu Masashi Mukoyama Katsumi Miyauchi Seiji Ho Source Type: research
Impact of High-Intensity Statin on Early Neurologic Deterioration in Patients with Single Small Subcortical Infarction
CONCLUSIONS: We identified an association between the intensity of early statin therapy and END in patients with SSSI. Early administration of high-intensity statin (≤24 h) is associated with a reduced incidence of END in patients with SSSI.PMID:37176701 | PMC:PMC10179331 | DOI:10.3390/jcm12093260
Source: Atherosclerosis - May 13, 2023 Category: Cardiology Authors: Seong Hwa Jang Hyungjong Park Jeong-Ho Hong Joonsang Yoo Hyung Lee Hyun Ah Kim Sung-Il Sohn Source Type: research
Efficacy and safety of the use of alirocumab in real clinical practice
CONCLUSION: The inclusion of alirocumab in the treatment regimen contributed to the stable course of atherosclerosis-associated diseases, the achievement of LDL cholesterol targets in 77.8% of patients, was not accompanied by side effects during 2.5 years therapy.PMID:37167185 | DOI:10.26442/00403660.2022.12.201991
Source: Atherosclerosis - May 11, 2023 Category: Cardiology Authors: V A Korneva T Y Kuznetsova I S Scopets N N Vezikova Source Type: research
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
CONCLUSIONS: In patients undergoing coronary angiography, Lp(a) and OxPL-apoB are associated with multivessel CAD. Lp(a), OxPL-apoB, and OxPL-apo(a) are associated with incident cardiovascular events. (Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA]; NCT00842868).PMID:37137588 | DOI:10.1016/j.jacc.2023.02.050
Source: Atherosclerosis - May 3, 2023 Category: Cardiology Authors: Thomas C Gilliland Yuxi Liu Reza Mohebi Hannah Miksenas Sara Haidermota Megan Wong Xingdi Hu Joaquim Rosado Cristino Auris Browne Jorge Plutzky Sotirios Tsimikas James L Januzzi Pradeep Natarajan Source Type: research
Predicting Statin Adherence Following Hospital Discharge for Acute Coronary Syndromes: What ’s the Score?
The use of statins following acute coronary syndromes (ACS) is well documented to improve mortality and reduce hospitalisation, revascularisation and risk of stroke [1], and has become a frequently used benchmark to audit in-hospital care of such patients. Much less is known about adherence to statins following discharge —and the factors influencing this—which is the subject of the paper by Liao et al. in this edition of Heart, Lung and Circulation [2].
Source: Heart, Lung and Circulation - May 1, 2023 Category: Cardiology Authors: Thomas R. Barlow, Sameer Karve, David Brieger, Harry C. Lowe Tags: Editorial Source Type: research
Statins Tied to Lower Stroke Risk in Atrial Fibrillation Statins Tied to Lower Stroke Risk in Atrial Fibrillation
Initiation of statins soon after diagnosis of AF is associated with lower risk of ischemic and hemorrhagic strokes; longer-term use is tied to further benefit, a new study shows.Medscape Medical News
Source: Medscape Cardiology Headlines - April 28, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Understanding the molecular mechanisms of statin pleiotropic effects
Arch Toxicol. 2023 Apr 21. doi: 10.1007/s00204-023-03492-6. Online ahead of print.ABSTRACTStatins represent the cornerstone of pharmacotherapy for the prevention of atherosclerotic cardiovascular disease. These medications not only reduce low-density lipoprotein cholesterol (LDL-C) via inhibition of 3-hydroxy-3-methylglutarate attached to CoA reductase, the key rate-limiting step in the cholesterol biosynthetic pathway, but also upregulate expression of the low-density lipoprotein receptor, improving serum clearance. Given LDL-C is a causal risk factor for the development of atherosclerosis, these complementary mechanisms ...
Source: Atherosclerosis - April 21, 2023 Category: Cardiology Authors: Charles A German James K Liao Source Type: research
The effect of intensive statin therapy in non-symptomatic intracranial arteries: The STAMINA-MRI sub-study
CONCLUSION: Intensive statin therapy produced a favorable morphological change in cerebral arteries of not only the target arterial segment but also non-symptomatic arterial segments. The change in cerebral arterial luminal diameter was influenced by the baseline SBP and was dependent on the topographic distribution of the cerebral arteries.Clinical Trial Registration: ClinicalTrials.gov, identifier NCT02458755.PMID:37056360 | PMC:PMC10088516 | DOI:10.3389/fneur.2023.1069502
Source: Atherosclerosis - April 14, 2023 Category: Cardiology Authors: Jae Eun Sim Ha-Na Song Jong-Un Choi Ji-Eun Lee In Young Baek Hwan-Ho Cho Jong-Hoon Kim Jong-Won Chung Gyeong-Moon Kim Hyun-Jin Park Oh Young Bang Woo-Keun Seo Source Type: research
Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction
ConclusionImplementation of guideline-recommended cholesterol-lowering therapy could prevent a substantial percentage of recurrent ASCVD events.
Source: Cardiovascular Drugs and Therapy - April 13, 2023 Category: Cardiology Source Type: research
